Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Taro Pharmaceutical Industries Ltd is a drug manufacturers-specialty & generic business based in the US. Taro Pharmaceutical Industries shares (TARO) are listed on the NYSE and all prices are listed in US Dollars. Taro Pharmaceutical Industries employs 1,417 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$64.83|
|52-week range||$53.95 - $80.00|
|50-day moving average||$70.29|
|200-day moving average||$72.75|
|Wall St. target price||$82.00|
|Dividend yield||N/A (13.23%)|
|Earnings per share (TTM)||$0.77|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-10)||-6.84%|
|1 month (2021-08-18)||-5.58%|
|3 months (2021-06-18)||-11.28%|
|6 months (2021-03-19)||-15.04%|
|1 year (2020-09-18)||11.78%|
|2 years (2019-09-18)||-20.68%|
|3 years (2018-09-18)||98.73|
|5 years (2016-09-16)||117.59|
Valuing Taro Pharmaceutical Industries stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Taro Pharmaceutical Industries's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Taro Pharmaceutical Industries's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 90x. In other words, Taro Pharmaceutical Industries shares trade at around 90x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Taro Pharmaceutical Industries's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $180.6 million.
The EBITDA is a measure of a Taro Pharmaceutical Industries's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$578.4 million|
|Operating margin TTM||27%|
|Gross profit TTM||$296.7 million|
|Return on assets TTM||4.07%|
|Return on equity TTM||1.83%|
|Market capitalisation||$2.6 billion|
TTM: trailing 12 months
There are currently 123,494 Taro Pharmaceutical Industries shares held short by investors – that's known as Taro Pharmaceutical Industries's "short interest". This figure is 2.3% up from 120,761 last month.
There are a few different ways that this level of interest in shorting Taro Pharmaceutical Industries shares can be evaluated.
Taro Pharmaceutical Industries's "short interest ratio" (SIR) is the quantity of Taro Pharmaceutical Industries shares currently shorted divided by the average quantity of Taro Pharmaceutical Industries shares traded daily (recently around 21074.061433447). Taro Pharmaceutical Industries's SIR currently stands at 5.86. In other words for every 100,000 Taro Pharmaceutical Industries shares traded daily on the market, roughly 5860 shares are currently held short.
However Taro Pharmaceutical Industries's short interest can also be evaluated against the total number of Taro Pharmaceutical Industries shares, or, against the total number of tradable Taro Pharmaceutical Industries shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Taro Pharmaceutical Industries's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Taro Pharmaceutical Industries shares in existence, roughly 0 shares are currently held short) or 0.0149% of the tradable shares (for every 100,000 tradable Taro Pharmaceutical Industries shares, roughly 15 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Taro Pharmaceutical Industries.
Find out more about how you can short Taro Pharmaceutical Industries stock.
We're not expecting Taro Pharmaceutical Industries to pay a dividend over the next 12 months.
Taro Pharmaceutical Industries's shares were split on a 2:1 basis on 26 July 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Taro Pharmaceutical Industries shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Taro Pharmaceutical Industries shares which in turn could have impacted Taro Pharmaceutical Industries's share price.
Over the last 12 months, Taro Pharmaceutical Industries's shares have ranged in value from as little as $53.95 up to $80. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Taro Pharmaceutical Industries's is 1.0409. This would suggest that Taro Pharmaceutical Industries's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Taro Pharmaceutical Industries Ltd. , a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprises allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1950 and is based in Haifa, Israel.
Everything we know about the MiNK Therapeutics IPO, plus information on how to buy in.
Everything we know about the Wetouch Technology IPO, plus information on how to buy in.
Everything we know about the Life Time Group Holdings IPO, plus information on how to buy in.
Everything we know about the Slinger Bag IPO, plus information on how to buy in.
Everything we know about the NSTS Bancorp IPO, plus information on how to buy in.
Everything we know about the Volcon IPO, plus information on how to buy in.
Everything we know about the Thomas James Homes IPO, plus information on how to buy in.
Everything we know about the FGI Industries IPO, plus information on how to buy in.
Everything we know about the Zhong Yang Financial Group IPO, plus information on how to buy in.
Everything we know about the Exscientia Ltd IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.